Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
IgA nephropathy is the most common primary glomerulonephritis in the world. Because of the
poor treatment effect in advanced patients, it is still the main cause of maintenance
dialysis. Current immunosuppressive therapy is still controversial, especially to those
progressive IgA nephropathy with eGFR<50ml/min. Leflunomide is widely used in the treatment
of rheumatic diseases, such as rheumatoid arthritis and lupus nephritis, it's serum
concentration will not be affected by renal function, and it also has antiviral effect. There
are two randomized controlled trials and a retrospective study suggesting that leflunomide
combined with glucocorticoids can effectively control urinary protein compared with
glucocorticoids or conservative treatment, but these three studies are not specifically
targeted at patients with estimated Glomerular Filtration Rate(eGFR) < 50ml/min.
Investigators will perform a prospective, open-label, randomized, controlled trial to
evaluate the efficacy and safety of leflunomide and low dose glucocorticoids therapy in
progressive IgA nephropathy with eGFR<50ml/min